杭州百诚医药科技股份有限公司 2024年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 杭州百诚医药科技股份有限公司（以下简称"公司"或"本公司"）经中国证券 监督管理委员会《关于同意杭州百诚医药科技股份有限公司首次公开发行股票注册的 批复》（证监许可〔2021〕3566 号），向社会公众公开发行人民币普通股（A 股）股 票 27,041,667 股，发行价为每股人民币 79.60 元，共计募集资金 2,152,516,693.20 元，扣除承销和保荐费用 261,877,503.98 元后的募集资金为 1,890,639,189.22 元， 已由主承销商国金证券股份有限公司于 2021 年 12 月 15 日汇入本公司募集资金监管 账户。另减除上网发行费、招股说明书印刷费、申报会计师费、律师费、评估费等与 发行权益性证券直接相关的新增外部费用 27,209,100.81 元后，公司本次募集资金净 额为 1,863,430,088.41 元。上述募集资金到位情况已 ...

提名人杭州百诚医药科技股份有限公司董事会现就提名袁弘 为杭州百诚医药科技股份有限公司第四届董事会独立董事候选人 发表公开声明。被提名人已书面同意作为杭州百诚医药科技股份 有限公司第四届董事会独立董事候选人(参见该独立董事候选人声 明)。本次提名是在充分了解被提名人职业、学历、职称、详细 的工作经历、全部兼职、有无重大失信等不良记录等情况后作 出的，本提名人认为被提名人符合相关法律、行政法规、部门规 章、规范性文件和深圳证券交易所业务规则对独立董事候选人 任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过杭州百诚医药科技股份有限公司第四 届董事会提名委员会或者独立董事专门会议资格审查，提名人 与被提名人不存在利害关系或者其他可能影响独立履职情形的 密切关系。 是 □否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百四 十六条等规定不得担任公司董事的情形。 是 □否 如否，请详细说明：______________________________ 三、被提名人符合中国证监会《上市公司独立董事管理办 法》和深圳证券交 ...

法定代表人： 主管会计工作的负责人 ： 会计机构负责人： 第 3 页 共 3 页 非经营性资金占用及其他关联资金往来情况汇总表 2024年度 | 编制单位：杭州百诚医药科技股份有限公司 | | | | | | | | | 单位：人民币万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的关 联关系 | 上市公司核算的 会计科目 | 2024年期初 占用资金余额 | 2024年度占用累计发生 金额 （不含利息） | 2024年度占用 资金的利息 （如有） | 2024年度偿还累计发 生金额 | 2024年期末 占用形成原因 占用资金余额 | 占用性质 | | 控股股东、实际控制人及其附属企业 | | | | | | | | | 非经营性占用 | | | | | | | | | | | 非经营性占用 | | 小 计 | - | - | - | | | | | | - | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | 非经营性占用 | | | ...

证券代码：301096 证券简称：百诚医药 公告编号：2025-024 杭州百诚医药科技股份有限公司 关于召开公司 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 杭州百诚医药科技股份有限公司（以下简称"公司"）定于2025年5月14日 （星期三）14:30召开2024年年度股东大会，本次会议采取现场表决与网络投票 相结合的方式召开，现将有关事项通知如下： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 14 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体 时间为 2025 年 5 月 14 日 9:15-15:00 期间的任意时间。 5、会议的召开方式：本次会议采用现场表决与网络投票相结合的方式召开。 公司将通过深圳证券交易所交易系统和互联网投票系统向全体股东提供网 络形式的投票平台，股东可以在本次会议网络投票时间段内通过上述系统行使表 决权。公司股东只能选择现场 ...

证券代码：301096 证券简称：百诚医药 公告编号：2025-021 第四届监事会第二次会议决议公告 本公司全体监事保证公告内容的真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 一、监事会会议召开情况 杭州百诚医药科技股份有限公司（以下简称"公司"）第四届监事会第二次会 议于 2025 年 4 月 22 日（星期二）在公司会议室以现场结合通讯的方式召开。会 议通知已于 2025 年 4 月 11 日通过邮件的方式送达各位监事。本次会议应出席监 事 3 人，实际出席监事 3 人（其中一位监事以通讯方式出席）。 会议由监事会主席胡富苗先生主持。会议召开符合有关法律、法规、规章和 《公司章程》的规定。出席会议的监事对各项议案进行了认真审议并做出了如下 决议： 二、监事会会议审议情况 （一）审议通过《关于<2024 年年度报告>及其摘要的议案》 经审核，监事会认为：公司董事会编制和审核的公司 2024 年年度报告全文 及摘要的程序符合法律、行政法规、中国证监会和深圳证券交易所的规定，报 告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误 导性陈述或者重大遗漏。 表决结果 ...

二、董事会会议审议情况 （一）审议通过《关于<2024 年年度报告>及其摘要的议案》 经审议，董事会认为：公司 2024 年年度报告全文及其摘要的内容真实、准 确、完整地反映了公司 2024 年度经营的实际情况，不存在任何虚假记载、误导 性陈述或者重大遗漏；报告编制和审核的程序符合法律、行政法规的要求，符合 中国证监会和深交所的相关规定，同意对外报出。 证券代码：301096 证券简称：百诚医药 公告编号：2025-020 杭州百诚医药科技股份有限公司 第四届董事会第二次会议决议公告 本公司全体董事、高级管理人员保证公告内容的真实、准确和完整，并对公 告中的虚假记载、误导性陈述或者重大遗漏承担责任。 一、董事会会议召开情况 杭州百诚医药科技股份有限公司（以下简称"公司"）第四届董事会第二次会 议于 2025 年 4 月 22 日在公司会议室以现场结合通讯的方式召开。会议通知已于 2025 年 4 月 11 日通过电话、邮件的方式送达各位董事。本次会议应出席董事 9 人，实际出席董事 9 人（其中四位董事以通讯方式出席）。 会议由董事长楼金芳女士主持，公司监事、高级管理人员列席会议。会议召 开符合有关法律、法规 ...

杭州百诚医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 22 日召开 第四届董事会第二次会议和第四届监事会第二次会议，均全票审议通过了《关于公司 2024 年度利润分配方案的议案》，本议案尚需提交 2024 年年度股东大会审议。 二、2024 年度利润分配方案情况 证券代码：301096 证券简称：百诚医药 公告编号：2025-023 杭州百诚医药科技股份有限公司 关于公司 2024 年度利润分配方案的公告 本公司全体董事、高级管理人员保证公告内容的真实、准确和完整，并对公告 中的虚假记载、误导性陈述或者重大遗漏承担责任。 一、审议程序 要充足的资金保障持续、稳定、健康发展，提升公司市场占有率和市场竞争力，提高 抗风险能力，更好地维护全体股东的长远利益。因此，公司决定 2024 年度拟不进行 利润分配。 根据天健会计师事务所（特殊普通合伙）审计，2024 年度实现归属于母公司股东 的净亏损 52,742,809.58 元。根据《上市公司监管指引第 3 号—上市公司现金分红》 《公司章程》及公司《未来三年（2024 年—2026 年）股东分红回报规划》等的有关规 定，因公司 2024 年度合并 ...

Financial Performance - The company's operating revenue for 2024 was ¥801,923,244.22, a decrease of 21.18% compared to ¥1,017,448,123.50 in 2023[21]. - The net profit attributable to shareholders for 2024 was -¥52,742,809.58, representing a decline of 119.39% from ¥271,966,149.52 in 2023[21]. - The cash flow from operating activities for 2024 was -¥195,856,925.64, a significant drop of 316.53% compared to ¥90,453,413.74 in 2023[21]. - The basic earnings per share for 2024 was -¥0.49, down 119.52% from ¥2.51 in 2023[21]. - The company reported a significant increase in credit impairment losses by 213.51% due to rising accounts receivable[76]. - The company reported a significant decline in operating income due to the impact of policies on its generic drug business, leading to a substantial decrease in profits[116]. Research and Development - The company is investing 30 million CNY in new technology to improve manufacturing processes and ensure compliance with Good Manufacturing Practices (GMP)[16]. - The company plans to increase its R&D budget by 15% to support the development of new drug candidates[16]. - The company has established a partnership with a leading research institution to accelerate drug discovery efforts[16]. - The company has developed a high-efficiency AI-driven drug research platform to explore new drug targets and optimize existing mature targets[39]. - The company is focusing on expanding its innovative drug pipeline and has several new projects under development[136]. Market Expansion and Strategy - The company is expanding its market presence, targeting an additional 10 provinces in China by the end of the fiscal year[16]. - The company aims to achieve a market share of 10% in the generic drug sector within the next two years[16]. - The company is actively pursuing mergers and acquisitions to enhance its product offerings and market presence, with a target of completing two acquisitions in the next year[136]. - The company plans to enter two new international markets by the end of 2024, aiming for a 10% market share in each[161]. Governance and Compliance - The report indicates that all board members attended the meeting to review the annual report, ensuring accountability for the report's accuracy[4]. - The financial report is guaranteed to be true, accurate, and complete by the company's responsible personnel[4]. - The company has established a performance evaluation and incentive mechanism to ensure transparency and fairness in governance[141]. - The company maintains independent operations in assets, personnel, finance, and business, ensuring no interference from controlling shareholders[143]. - The company is committed to complying with regulatory requirements in the pharmaceutical industry to mitigate risks related to policy changes[132]. Future Outlook - The company provided a positive outlook for the next quarter, projecting a revenue growth of 20% to 600 million CNY[16]. - Future plans and development strategies mentioned in the report do not constitute commitments to investors, highlighting potential investment risks[5]. - The company aims to submit IND applications for several new drug candidates by 2025, enhancing its pipeline in the neuropathic pain and oncology sectors[97]. - The company has set ambitious performance targets for the next fiscal year, aiming for a significant increase in revenue[153]. Employee and Management Structure - The company employed 1,834 staff as of December 31, 2024, with 69.47% in technical R&D roles[74]. - The company has implemented a competitive and fair compensation system, aligning employee salaries with job responsibilities and performance contributions[179]. - The company has a stable management team with no significant changes in executive positions reported[149]. - The company has established a mentorship program to foster talent development, incentivizing mentors through awards[181]. Risk Management - The company acknowledges the risks associated with drug development failures and is implementing measures to strengthen its R&D team and optimize drug development processes[128][129]. - The company is aware of the long drug development cycles and is actively monitoring policy changes to mitigate risks related to project delays[130]. - The company has not experienced major environmental or safety incidents but recognizes the potential risks and is enhancing safety management practices[132]. Investment and Funding - The company reported a total fundraising amount of RMB 2,152,516,693.20, with a net amount of RMB 1,863,430,088.41 after deducting issuance costs of RMB 289,086,604.79[113]. - The company has allocated RMB 36,387.00 million of the oversubscription funds for permanent working capital, not exceeding 30% of the total oversubscription amount[116]. - The company has increased its investment in innovative drug research and development to counteract the decline in revenue[116]. Product Development - New product development includes the launch of a generic drug expected to generate 100 million CNY in revenue within the first year[16]. - The company is actively pursuing new drug developments, with 12 drugs in the submission stage for Class 3 and Class 4 combined[46]. - The company has submitted applications for 10 drugs in Class 3, including treatments for obstructive airway diseases and type 2 diabetes[45].

Financial Performance - The company's revenue for Q1 2025 was ¥128,727,480.49, a decrease of 40.32% compared to ¥215,702,841.54 in the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥26,197,617.81, representing a decline of 152.59% from a profit of ¥49,818,209.14 in the previous year[4]. - Total operating revenue for the current period was ¥128,727,480.49, a decrease of 40.4% compared to ¥215,702,841.54 in the previous period[18]. - Net profit for the current period was a loss of ¥26,197,617.81, compared to a profit of ¥49,818,209.14 in the previous period, representing a significant decline[19]. - Basic and diluted earnings per share for the current period were both -¥0.24, compared to ¥0.46 in the previous period[20]. - Other comprehensive income after tax for the current period was -¥32,349.31, compared to -¥1,349.85 in the previous period[19]. Cash Flow - The net cash flow from operating activities improved by 42.59%, amounting to -¥70,028,927.58 compared to -¥121,975,608.72 in the prior year[4]. - The company reported a total of ¥108,725,148.09 in cash inflows from operating activities, a decrease from ¥110,905,629.87 in the previous period[21]. - Investment activities generated cash inflows of ¥128,032,273.42, compared to ¥97,926,542.60 in the previous period, indicating a positive trend in investment recovery[21]. - Net cash flow from investment activities was -$88.79 million, a decrease from -$233.07 million in the previous period[22]. - Cash inflow from financing activities totaled $200 million, down from $514 million in the prior period[22]. - Cash outflow for debt repayment was $80 million, compared to $249.50 million previously[22]. - The net increase in cash and cash equivalents was -$43.19 million, improving from -$93.80 million in the previous period[22]. - The ending balance of cash and cash equivalents was $372.97 million, down from $684.65 million at the end of the previous period[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,773,885,876.81, reflecting a 1.42% increase from ¥3,721,188,515.50 at the end of the previous year[4]. - Current assets totaled CNY 1,610,431,297.78, up from CNY 1,545,474,358.29 at the start of the period, reflecting a growth of approximately 4.9%[14]. - Total liabilities rose to CNY 1,220,726,059.65 from CNY 1,141,798,731.22, reflecting an increase of about 6.9%[15]. - The company's equity remained stable with total equity at CNY 2,553,159,817.16, consistent with previous periods[15]. - The company reported a significant increase in contract assets, which rose to CNY 390,159,165.61 from CNY 379,655,510.32, indicating a growth of approximately 2.6%[14]. Expenses - The company experienced a 368.22% increase in financial expenses, totaling ¥3,443,240.34, primarily due to increased loan amounts and interest expenses[8]. - Total operating costs increased slightly to ¥164,765,613.68 from ¥164,553,615.62, with operating costs rising to ¥75,155,234.89 from ¥68,611,172.02[18]. - Research and development expenses decreased to ¥54,466,161.55 from ¥65,271,951.41, indicating a reduction in investment in innovation[18]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,188, with no preferred shareholders[10]. Government Support - The company received government subsidies amounting to ¥8,473,176.69, contributing to other income growth of 634.24%[8]. Return on Equity - The company's weighted average return on equity decreased to -1.02% from 1.84% in the previous year[4].

Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) has revised its 2024 annual performance forecast, projecting a net loss of 31.5 million to 53.5 million yuan, a significant shift from the previously expected profit of 45 million to 65 million yuan [1][2]. Summary by Relevant Sections - **Performance Forecast Revision** - The company expects to report a net loss for 2024, marking a potential first annual loss since its listing in 2021 [1][2]. - The revised forecast indicates a substantial decline from the previous year's profit of 272 million yuan [2]. - **Factors Influencing the Revision** - The annual audit was not fully underway when the initial forecast was made, leading to a cautious approach in revenue recognition, resulting in a revenue reduction of 40 million yuan due to indications of contract termination in R&D projects [2]. - The company decided not to recognize deferred tax assets related to deductible temporary differences, leading to an increase in income tax expenses by 45 million yuan [2]. - A comprehensive assessment of accounts receivable resulted in specific provisions for bad debts, decreasing pre-tax profit by 10 million yuan [2].